If Keytruda can get 100% occupancy then blocking it. If leronlimab can sufficiently downregulate it then there wouldn't be much difference between the two. Even if there's a decent amount of downregulation combining it with Keytuda might not be the best because of Keytruda's side effects.
If I remember correctly they are checking for PD-1 expression in the trials.